Article
ALK in Neuroblastoma: Biological and Therapeutic Implications
10 Apr 2018
Abstract excerpt
Neuroblastoma (NB) is the most common and deadly solid tumour in children. Despite the development of new treatment options for high-risk NB, over half of patients relapse and five-year survival remains at 40–50%. Therefore, novel treatment strategies aimed at providing long-term disease remission are urgently sought. ALK, encoding the anaplastic lymphoma kinase receptor, is altered by gain-of-function point...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
